Gelesis Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
56
- Latest Deal Type
-
M&A
Gelesis General Information
Description
Gelesis Holdings Inc is a commercial-stage biotherapeutics company built for consumer engagement. The company is focused on advancing its superabsorbent hydrogel therapeutics for chronic gastrointestinal diseases, including excess weight, type 2 diabetes, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), functional constipation (FC), and inflammatory bowel disease. It manufactures and markets Plenity, which is based on a proprietary hydrogel technology, to aid in weight management when used in conjunction with diet and exercise. Geographically, the company operates out of the U.S. and Italy.
Contact Information
Website
www.gelesis.com(Operating Subsidiary)
Corporate Office
- Via Europa, SP26, 187
- Suite 6102
- 73021 Calimera(Leece)
- Italy
Corporate Office
- Via Europa, SP26, 187
- Suite 6102
- 73021 Calimera(Leece)
- Italy
Gelesis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 24. Merger/Acquisition | 08-Jul-2024 | Completed | Generating Revenue | |||
| 23. Bankruptcy: Admin/Reorg | 30-Oct-2023 | Completed | Bankruptcy: Admin/Reorg | |||
| 22. PIPE | 11-Aug-2022 | Completed | Generating Revenue | |||
| 21. PIPE | 14-Jan-2022 | Completed | Generating Revenue | |||
| 20. Reverse Merger | 13-Jan-2022 | Completed | Generating Revenue | |||
| 19. Debt - General | 01-Mar-2021 | Completed | Generating Revenue | |||
| 18. Secondary Transaction - Private | 18-Jan-2021 | Completed | Generating Revenue | |||
| 17. Debt - General | 31-Dec-2020 | Completed | Generating Revenue | |||
| 16. Later Stage VC | 29-Jul-2020 | $84.6M | $305M | Completed | Generating Revenue | |
| 15. Debt - PPP | 15-Apr-2020 | $297K | $220M | Completed | Generating Revenue |
Gelesis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series 4 Growth | ||||||||
| Series 3 Growth | ||||||||
| Series 2 Growth | ||||||||
| Growth Pref | ||||||||
| Series A5 | ||||||||
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | 1,161,254 | $0.000100 | 8% | $2.61 | $2.61 | 1x | $2.61 | 3.51% |
| Series A1 | 1,711,755 | $0.000100 | 8% | $4.44 | $4.44 | 1x | $4.44 | 5.18% |
Gelesis Comparisons
Industry
Financing
Details
Gelesis Competitors (28)
One of Gelesis’s 28 competitors is Vivus, a Corporate Backed or Acquired company based in Campbell, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vivus | Corporate Backed or Acquired | Campbell, CA | ||||
| Savara | Formerly VC-backed | Yardley, PA | ||||
| Sharp Therapeutics (Biotechnology) | Formerly VC-backed | Pittsburgh, PA | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Gelesis Signals
Gelesis Former Investors (28)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Andera Partners | PE/Buyout | Minority | ||
| BIRD Foundation | Limited Partner | |||
| BRC Group Holdings | Holding Company | Minority | ||
| Cape Family Fund | Venture Capital | Minority | ||
| Capstar Special Purpose Acquisition | Special Purpose Acquisition Company (SPAC) | Minority |
Gelesis Acquisitions (2)
Gelesis’s most recent deal was a Merger/Acquisition with Capstar Special Purpose Acquisition. The deal was made on 13-Jan-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Capstar Special Purpose Acquisition | 13-Jan-2022 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Academica Life Science | 01-Feb-2015 | Merger/Acquisition | Industrial Chemicals |
Gelesis ESG
Risk Overview
Risk Rating
Updated April, 30, 2023
29.2 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,942
Rank
Percentile
Pharmaceuticals
Industry
of 914
Rank
Percentile
Biotechnology
Subindustry
of 412
Rank
Percentile
Gelesis FAQs
-
When was Gelesis founded?
Gelesis was founded in 2006.
-
Where is Gelesis headquartered?
Gelesis is headquartered in Calimera, Italy.
-
What is the size of Gelesis?
Gelesis has 56 total employees.
-
What industry is Gelesis in?
Gelesis’s primary industry is Drug Discovery.
-
Is Gelesis a private or public company?
Gelesis is a Private company.
-
What is Gelesis’s current revenue?
The current revenue for Gelesis is .
-
How much funding has Gelesis raised over time?
Gelesis has raised $422M.
-
Who are Gelesis’s investors?
Andera Partners, BIRD Foundation, BRC Group Holdings, Cape Family Fund, and Capstar Special Purpose Acquisition are 5 of 28 investors who have invested in Gelesis.
-
Who are Gelesis’s competitors?
Vivus, Savara, Sharp Therapeutics (Biotechnology), uniQure, and Immunocore Holdings are some of the 28 competitors of Gelesis.
-
When was Gelesis acquired?
Gelesis was acquired on 08-Jul-2024.
-
Who acquired Gelesis?
Gelesis was acquired by Theras Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process